Neudive's Buddy-in Featured in Report on Potential Value and Impact of Digital Therapeutics (DTx)

Neudive's 'Autism Spectrum Disorder Social Skills Digital Therapeutic,' Buddy-in, was included as one of two products featured in the Digital Therapeutics Potential Value and Impact Assessment Research Report published in December 2023 by the National Evidence-based Healthcare Collaborating Agency (NECA) and the Korea Health Industry Development Institute (KHIDI). The selection was evaluated based on digital healthcare policy demand and domestic market entry potential. The report introduces Buddy-in's target indication, anticipated dosage and usage, and current stage of development.